GCG and type 1 diabetes mellitus: A SSTR2a, ZT-01, produced by Zucara Therapeutics is currently in phase II clinical trials for preventing nocturnal hypoglycemia in individuals with T1D after successfully completing a phase I clinical study whereby 90% of T1D subjects undergoing a hypoglycemic clamp demonstrated an improved glucagon response in the presence of ZT-01 [254,255].